Abciximab and excessive bleeding in patients undergoing emergency cardiac operations

Annals of Thoracic Surgery

Volumn 65, Issue 2, 1998, Pages 465-469

  Gammie, James S ^a   Zenati, Marco ^a   Kormos, Robert L ^a   Hattler, Brack G ^a   Wei, Lawrence M ^a   Pellegrini, Ronald V ^a   Griffith, Bartley P ^a   Dyke, Cornelius M ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB;

ADULT; AGED; ANGIOPLASTY; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CORONARY ARTERY DILATATION; EMERGENCY SURGERY; ERYTHROCYTE TRANSFUSION; FEMALE; HEART SURGERY; HUMAN; MALE; PRIORITY JOURNAL; STENT; THORAX DRAINAGE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BLOOD LOSS, SURGICAL; CARDIAC SURGICAL PROCEDURES; EMERGENCY TREATMENT; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE;

EID: 0032005728     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(97)01299-X     Document Type: Article

References (16)

1. 1. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330: 956-61.
2. 2. Abciximab product information, Centocor Labs, 1996.
3. 3. LeBreton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996;28:1643-51.
4. 4. Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-8.
5. 5. Coller BS, Scudder LE, Beer J, et al. Monoclonal antibodies to platelet GPIIb/IIIa as antithrombotic agents. Ann NY Acad Sci 1991;614:193-213.
6. 6. Coller BS. Inhibitors of the platelet glycoprotein IIb/IIIa receptor as conjunctive therapy for coronary artery thrombolysis. Coron Artery Dis 1992;3:1016-29.
7. 7. Mascelli MA, Lance ET, Wagner CL, Weisman HF, Jordan RE. Abciximab (7E3) pharmacodynamics demonstrates an extended and gradual recovery from GPIIb/IIIa blockade. Circulation 1996;94(Suppl):3008.
8. 8. Aguirre FV, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-90.
9. 9. Belisle S, Hardy JF. Hemorrhage and the use of blood products after adult cardiac operations: myths and realities. Ann Thorac Surg 1996;62:1908-17.
10. 10. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or direction atherectomy (the EPIC trial). Am J Cardiol 1995;75:559-62.
11. 11. Coller BS, Anderson K, Weisman HF. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 1995;74:302-8.
12. 12. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 on the activated clotting time. Circulation 1997;95:614-7.
13. 13. Reverter JC, Kessels H, Beguin S, et al. Platelet glycoprotein IIb/IIIa inhibition decreases thrombin generation induced by tissue factor [Abstract]. Blood 1994;84:470a.
14. 14. Tcheng JE, Harrington RA, Kottke-Marchant K, for the IMPACT Investigators. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrilin in elective coronary intervention. Circulation 1995;91:2151-7.
15. 15. Ferguson JJ. EPILOG and CAPTURE trials halted because of positive interim results. Circulation 1996;93:637.
16. 16. Van de Werf F. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. Eur Heart J 1996;17:325-6.